Asper Biogene OÜ
Asper Biogene OÜ is a OÜ based in Tartu linn, registry code 14265334, status: active. Main activity: Research and experimental development on natural sciences and engineering. According to EMTA, turnover for Q3 2026 was €43 017 with 11 employees.
Q3 2026 · data from the Tax and Customs Board (EMTA)
Position in the industry
- Turnover · Q3 2026 43 017 €above 73% of companiesindustry median 14 442 € · companies in the industry: 318
- Labour taxes per employee 1 844 €above 45% of companiesindustry median 2 218 € · companies in the industry: 234
- Revenue · 2025 589 232 €above 98% of companiesindustry median 0 € · companies in the industry: 1 073
- Net profit margin · 2025 -28.5 %above 16% of companiesindustry median 13.5 % · companies in the industry: 597
Taxes and turnover
- Company
- Industry median
Industry: Scientific research and development (the EMTAK division of the main activity). Median: half of the industry is above, half below.
- Company
- Industry median
Industry: Scientific research and development (the EMTAK division of the main activity). Median: half of the industry is above, half below.
| Quarter | Turnover, € | State taxes, € | Labour taxes, € | Employees |
|---|---|---|---|---|
| Q3 2026 | 43 017 | 23 311 | 20 288 | 11 |
| Q2 2026 | 62 570 | 27 370 | 19 577 | 11 |
| Q1 2026 | 61 730 | 40 977 | 28 024 | 11 |
| Q4 2025 | 53 643 | 32 395 | 25 565 | 12 |
| Q3 2025 | 62 090 | 31 812 | 24 010 | 13 |
| Q2 2025 | 72 390 | 33 329 | 24 406 | 13 |
| Q1 2025 | 50 100 | 26 123 | 23 024 | 13 |
| Q4 2024 | 72 541 | 27 162 | 20 580 | 13 |
| Q3 2024 | 67 212 | 33 350 | 24 121 | 13 |
| Q2 2024 | 85 182 | 36 851 | 30 520 | 13 |
| Q1 2024 | 80 267 | 26 583 | 29 172 | 13 |
| Q4 2023 | 113 169 | 38 350 | 24 729 | 11 |
| Q3 2023 | 58 625 | 29 034 | 24 126 | 11 |
| Q2 2023 | 99 903 | 37 958 | 25 547 | 11 |
| Q1 2023 | 110 961 | 49 657 | 26 425 | 12 |
| Q4 2022 | 51 714 | 26 755 | 25 455 | 13 |
| Q3 2022 | 49 688 | 26 415 | 24 262 | 13 |
| Q2 2022 | 55 024 | 38 984 | 26 883 | 13 |
| Q1 2022 | 67 088 | 35 713 | 30 893 | 14 |
Q3 2026 · calculated from EMTA data
Financials by year
- Company
- Industry median
Industry: Scientific research and development (the EMTAK division of the main activity). Median: half of the industry is above, half below.
- Company
- Industry median
Industry: Scientific research and development (the EMTAK division of the main activity). Median: half of the industry is above, half below.
- Company
- Industry median
Industry: Scientific research and development (the EMTAK division of the main activity). Median: half of the industry is above, half below.
- Company
- Industry median
Industry: Scientific research and development (the EMTAK division of the main activity). Median: half of the industry is above, half below.
| Year | Revenue, € | Net profit, € | Labour costs, € | Assets, € | Equity, € | Employees |
|---|---|---|---|---|---|---|
| 2025 | 589 232 | -167 803 | 229 140 | 227 003 | 112 647 | 9 |
| 2024 | 649 888 | -66 368 | 235 642 | 391 956 | 280 450 | 9 |
| 2023 | 825 111 | 14 628 | 247 828 | 491 614 | 346 818 | 9 |
| 2022 | 782 438 | 155 811 | 257 392 | 594 688 | 332 190 | 9 |
| 2021 | 651 969 | 35 465 | 320 432 | 422 487 | 176 379 | 11 |
| 2020 | 786 521 | 40 641 | 316 976 | 353 107 | 140 914 | 13 |
| 2019 | 681 879 | 14 050 | 334 403 | 323 817 | 100 273 | 14 |
| 2018 | — | — | — | — | — | 17 |
| 2017 | — | — | — | — | — | 17 |
Figures from the company’s own (non-consolidated) balance sheet and income statement. A loss is shown with a minus sign.
Financial ratios for 2025
Annual reports
| Year | Period | Filed | Report | Documents |
|---|---|---|---|---|
| 2025 | 1 Jan 2025 – 31 Dec 2025 | 30 Jun 2026 | Company’s own | e-Äriregister |
| 2024 | 1 Jan 2024 – 31 Dec 2024 | 30 Jun 2025 | Company’s own | e-Äriregister |
| 2023 | 1 Jan 2023 – 31 Dec 2023 | 27 Jun 2024 | Company’s own | e-Äriregister |
| 2022 | 1 Jan 2022 – 31 Dec 2022 | 26 Jun 2023 | Company’s own | e-Äriregister |
| 2021 | 1 Jan 2021 – 31 Dec 2021 | 30 Jun 2022 | Company’s own · audited | e-Äriregister |
| 2020 | 1 Jan 2020 – 31 Dec 2020 | 25 Jun 2021 | Company’s own · audited | e-Äriregister |
| 2019 | 1 Jan 2019 – 31 Dec 2019 | 2 Jul 2020 | Company’s own · audited | e-Äriregister |
Board
- Hardi TammBoard member · since 8 Jun 2021
Right of representation
Any member of the management board may represent the private limited company in all transactions.
Owners
- OÜ Asper BiolabLegal person · 11538286 · 2 500 €
Beneficial owners
- Katrin TammIndirect ownership · since 17 Jun 2022
- Hardi TammIndirect ownership · since 25 Jun 2021
Founders and other persons
- Villem AruojaFounder · 2 500 € · 23 May 2017
Related companies
Activities (EMTAK)
- 72101Research and experimental development on natural sciences and engineering Main
Rulings
All rulings (PDF)| Number, date | Title | Deadline | State | Document |
|---|---|---|---|---|
| Ä 50057920 / 12 18 Nov 2024 |
Amendment entry | In force 18 Nov 2024 |
||
| Ä 50057920 / 11 2 Sep 2023 |
Amendment entry | In force 2 Sep 2023 |
||
| Ä 50057920 / 10 30 Jun 2023 |
Amendment entry | In force 30 Jun 2023 |
||
| Ä 50057920 / 9 8 Jun 2021 |
Amendment entry | In force 8 Jun 2021 |
||
| Ä 50057920 / 8 18 Feb 2020 |
Amendment entry | In force 18 Feb 2020 |
||
| Ä 50057920 / 7 3 Jan 2020 |
Amendment entry | In force 3 Jan 2020 |
||
| Ä 50057920 / M2 30 Dec 2019 |
Ruling to eliminate deficiencies | 19 Jan 2020 | Deficiencies eliminated 3 Jan 2020 |
|
| Ä 50057920 / 6 26 Nov 2019 |
Amendment entry | In force 26 Nov 2019 |
||
| Ä 50057920 / 5 30 Jun 2018 |
Amendment entry | In force 30 Jun 2018 |
||
| Ä 50057920 / 4 20 Jan 2018 |
Amendment entry | In force 20 Jan 2018 |
||
| Ä 50057920 / 3 13 Dec 2017 |
Amendment entry | In force 13 Dec 2017 |
||
| Ä 50057920 / 2 11 Jul 2017 |
Amendment entry | In force 11 Jul 2017 |
||
| Ä 50057920 / M1 7 Jul 2017 |
Ruling to eliminate deficiencies | 27 Jul 2017 | Deficiencies eliminated 10 Jul 2017 |
|
| Ä 50057920 24 May 2017 |
First entry | In force 24 May 2017 |
Sources: e-Äriregister and EMTA. Data updated 31 Oct 2026. Open at the source ↗ · Report an error in the data